Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kymera Therapeutics Inc KYMR

Healthcare Biotechnology
Kymera Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. The Company's targeted protein degradation (TPD) platform, which it refers to as Pegasus, allows it to discover highly selective small... see more

Recent & Breaking News (NDAQ:KYMR)

Kymera Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021

GlobeNewswire January 5, 2021

Kymera Therapeutics Announces Key Leadership Appointments

GlobeNewswire December 16, 2020

Kymera Therapeutics Presents Preclinical Data on IRAKIMiD and STAT3 Programs at Virtual 62nd American Society of Hematology (ASH) Annual Meeting

GlobeNewswire December 7, 2020

Kymera Therapeutics to Present at the Piper Sandler 32nd Annual Healthcare Conference

GlobeNewswire November 23, 2020

Kymera Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference

GlobeNewswire November 11, 2020

Kymera Therapeutics Announces Third Quarter 2020 Financial Results and Provides Business Update

GlobeNewswire November 5, 2020

Kymera Therapeutics to Present Data on Novel IRAKIMiD and STAT3 Protein Degraders at Virtual 62nd American Society of Hematology (ASH) Annual Meeting

GlobeNewswire November 4, 2020

Kymera Therapeutics to Deliver Two Podium Presentations at 3rd Annual Targeted Protein Degradation Summit

GlobeNewswire October 12, 2020

Kymera Therapeutics to Present Interim Results from a Non-Interventional Study Characterizing IRAK4 Expression and Demonstrating Proof of Mechanism of an IRAK4 Degrader in Patients with Hidradenitis Suppurativa

GlobeNewswire October 9, 2020

Kymera Therapeutics to Present at Morgan Stanley 18th Annual Global Healthcare Conference

GlobeNewswire September 14, 2020

Kymera Therapeutics Appoints Biopharma Veterans Pamela Esposito and Jeff Albers to its Board of Directors

GlobeNewswire September 9, 2020

Kymera Therapeutics Appoints Dr. Richard Chesworth as Chief Scientific Officer

GlobeNewswire August 27, 2020

Kymera Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement

GlobeNewswire August 25, 2020

Kymera Therapeutics Announces Pricing of Upsized Initial Public Offering

GlobeNewswire August 20, 2020